Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. develops and commercializes autoimmune diagnostic testing products under the AVISE brand. The company’s flagship AVISE CTD test is used by clinicians in evaluating complex rheumatic and autoimmune diseases, including lupus, rheumatoid arthritis and Sjögren’s disease, and its CLIA-certified, CAP-accredited laboratory specializes in rheumatic disease testing.
Recurring news for XGN includes quarterly and annual financial results, AVISE CTD test volume, average selling price, revenue, gross margin and cash updates. Company announcements also cover autoimmune biomarker research, additions to the AVISE testing portfolio, conference participation and corporate updates tied to Exagen’s diagnostics business.
Exagen (Nasdaq:XGN) reported record Q1 2026 revenue of $17.3 million, up 12% year over year, with gross margin of 59.0% and AVISE CTD test volume up 10%.
Trailing-twelve-month AVISE CTD ASP rose 6% to $444. Net loss was $4.0 million and adjusted EBITDA loss improved to $2.2 million. Cash and equivalents were about $22 million. Full-year 2026 revenue guidance remains $70–$73 million.
Exagen (Nasdaq: XGN) will release financial results for the quarter ended March 31, 2026, before the market opens on May 11, 2026.
John Aballi, President and CEO, and Jeff Black, CFO, will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) that day. Webcast and replay will be available via the Exagen Investor Relations website; telephone replay available through May 25, 2026.
Exagen (NASDAQ: XGN) reported record 2025 results with $66.6M total revenue, a 20% increase, and AVISE CTD test volume growth of >11%. Trailing-twelve-month ASP rose to $441 (+7%). Company ended 2025 with $32.4M cash and raised capital via a $20M public offering and $25M credit facility.
Net loss was $19.95M for the year; 2026 revenue guidance is $70M–$73M.
Exagen (Nasdaq: XGN) announced management will participate in two investor conferences in March 2026: a virtual KeyBank Capital Markets Healthcare Forum on March 17, 2026 (investor meetings and a fireside chat at 3:00 p.m. ET) and the Roth Capital Conference in Laguna Niguel on March 23, 2026 (investor meetings).
Exagen (Nasdaq: XGN) will release fourth quarter and full year 2025 financial results before market open on March 10, 2026. Management will host a live conference call and webcast to review results.
Details: the call with CEO John Aballi and CFO Jeff Black is at 8:30 a.m. ET / 5:30 a.m. PT; a live webcast and a recorded replay will be available via the company investor relations website.
Exagen (Nasdaq: XGN) reported select preliminary unaudited results for the quarter and year ended December 31, 2025, consistent with prior guidance. Full-year revenue is projected at $66M–$67M, a 19%–20% increase versus 2024, and Q4 revenue is projected at $16M–$17M (up 17%–24%). The AVISE CTD test volume is 136,000–137,000 (TTM) with an ASP of $441–$445, an increase of at least $30 versus 2024. Year-end cash and cash equivalents were $32M, a $10M increase versus 2024. Results are preliminary and unaudited.
Exagen (Nasdaq: XGN) said management will participate in two investor conferences in New York in November 2025: the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at Sheraton New York Times Square, and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025 at Westin NY Grand Central.
The appearances provide opportunities for investor updates and one‑on‑one meetings with company management.
Exagen (Nasdaq: XGN) reported Q3 2025 results: revenue $17.2M (up 38% year-over-year), gross margin 58.4%, and trailing-twelve-month ASP $441 (up $37 vs Q3 2024). The company ended Q3 with $35.7M cash and reduced adjusted EBITDA loss to $(1.9)M for the quarter. Exagen commercially launched seronegative RA anti-PAD4 markers and presented research at ACR. The company reiterated full-year 2025 revenue guidance of $65M–$70M and said it could reach positive adjusted EBITDA in Q4 at the high end of that range.
Exagen (Nasdaq: XGN) announced acceptance of six abstracts for ACR Convergence 2025, held Oct 24–29, 2025 in Chicago. The program includes a plenary presentation on Oct 27 highlighting a urinary tenascin C panel that may predict kidney function loss in lupus nephritis and several posters on anti-RA33, anti-PAD4, T cell biomarkers, a kidney-specific four-protein index, and a multianalyte lupus risk score to improve AVISE CTD diagnostic precision.
Exagen will host an Innovation Theater on Oct 27, 2:30–3:15pm CDT and staff the booth #1228 for follow-up.
Exagen (Nasdaq: XGN) will release financial results for the quarter ended September 30, 2025 before the market opens on Tuesday, November 4, 2025. A conference call and webcast to review results will be held at 8:30 a.m. ET / 5:30 a.m. PT with John Aballi, President and CEO, and Jeff Black, CFO.
Conference call details: U.S. dial-in 201-389-0918; international dial-in 877-407-0890; webcast available at investors.exagen.com. A telephone replay is available through Tuesday, November 18, 2025 (U.S. replay 201-612-7415; international replay 877-660-6853; replay passcode 13756599). A recording of the webcast will be posted about one hour after the call at investors.exagen.com.